Treatment of premenstrual dysphoric disorder with the GABAA receptor modulating steroid antagonist Sepranolone (UC1010)—A randomized controlled trial

Psychoneuroendocrinology

Volumn 80, Issue , 2017, Pages 46-55

  Bixo, Marie ^a   Ekberg, Karin ^b   Poromaa, Inger Sundström ^c   Hirschberg, Angelica Lindén ^d   Jonasson, Aino Fianu ^d   Andréen, Lotta ^e   Timby, Erika ^a   Wulff, Marianne ^f   Ehrenborg, Agneta ^g   Bäckström, Torbjörn ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b Asarina Pharma AB   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e SUNDSVALL HOSPITAL   (Sweden)

^f Portuguese Sports Institute   (Portugal)

^g Specialistläkarna Kungsbacka Qvinnolivet   (Sweden)

Author keywords

Allopregnanolone; GABA; Isoallopregnanolone; Premenstrual dysphoric disorder; Randomized controlled trial

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; 4 AMINOBUTYRIC ACID A RECEPTOR; PLACEBO; SEPRANOLONE; 4 AMINOBUTYRIC ACID A RECEPTOR BLOCKING AGENT; ELTANOLONE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; SEROTONIN UPTAKE INHIBITOR;

ADULT; ALGORITHM; ANGER; ANXIETY; ARTICLE; ASSESSMENT OF HUMANS; CONTROLLED STUDY; DAILY RECORD OF SEVERITY OF PROBLEMS; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; EFFECT SIZE; ENDICOTT ALGORITHM; FEMALE; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE SWELLING; IRRITABILITY; LABILITY; LUTEAL PHASE; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; MOLECULAR INTERACTION; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POST HOC ANALYSIS; PREMENSTRUAL DYSPHORIC DISORDER; RANDOMIZED CONTROLLED TRIAL; SYMPTOM; AFFECT; DRUG EFFECTS; FOLLICULAR PHASE; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PREMENSTRUAL SYNDROME;

ADULT; AFFECT; ANGER; ANXIETY; CONTRACEPTIVES, ORAL; DEPRESSION; DOUBLE-BLIND METHOD; FEMALE; FOLLICULAR PHASE; GABA-A RECEPTOR ANTAGONISTS; HUMANS; LUTEAL PHASE; MENSTRUAL CYCLE; MIDDLE AGED; PREGNANOLONE; PREMENSTRUAL DYSPHORIC DISORDER; PREMENSTRUAL SYNDROME; PROGESTERONE; RECEPTORS, GABA-A; SEROTONIN UPTAKE INHIBITORS;

EID: 85015677656     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2017.02.031     Document Type: Article

References (52)

1. APA, The Diagnostic and Statistical Manual of Mental Disorders. 2013, American Psychiatric Association.
2. Andreen, L., Sundstrom-Poromaa, I., Bixo, M., Nyberg, S., Backstrom, T., Allopregnanolone concentration and mood–a bimodal association in postmenopausal women treated with oral progesterone. Psychopharmacology (Berl) 187 (2006), 209–221.
3. Andreen, L., Nyberg, S., Turkmen, S., van Wingen, G., Fernandez, G., Backstrom, T., Sex steroid induced negative mood may be explained by the paradoxical effect mediated by GABAA modulators. Psychoneuroendocrinology 34 (2009), 1121–1132.
4. Backstrom, T., Andreen, L., Birzniece, V., Bjorn, I., Johansson, I.M., Nordenstam-Haghjo, M., Nyberg, S., Sundstrom-Poromaa, I., Wahlstrom, G., Wang, M., Zhu, D., The role of hormones and hormonal treatments in premenstrual syndrome. CNS Drugs 17 (2003), 325–342.
5. Backstrom, T., Wahlstrom, G., Wahlstrom, K., Zhu, D., Wang, M.D., Isoallopregnanolone; an antagonist to the anaesthetic effect of allopregnanolone in male rats. Eur. J. Pharmacol. 512 (2005), 15–21.
6. Belelli, D., Casula, A., Ling, A., Lambert, J.J., The influence of subunit composition on the interaction of neurosteroids with GABA(A) receptors. Neuropharmacology 43 (2002), 651–661.
7. Bengtsson, S.K., Nyberg, S., Hedstrom, H., Zingmark, E., Jonsson, B., Backstrom, T., Bixo, M., Isoallopregnanolone antagonize allopregnanolone-induced effects on saccadic eye velocity and self-reported sedation in humans. Psychoneuroendocrinology 52 (2015), 22–31.
8. Bixo, M., Andersson, A., Winblad, B., Purdy, R.H., Backstrom, T., Progesterone, 5alpha-pregnane-3,20-dione and 3alpha-hydroxy-5alpha-pregnane-20-one in specific regions of the human female brain in different endocrine states. Brain Res. 764 (1997), 173–178.
9. Bramness, J.G., Skurtveit, S., Morland, J., Flunitrazepam: psychomotor impairment, agitation and paradoxical reactions. Forensic Sci. Int. 159 (2006), 83–91.
10. Bristot, G., Ascoli, B., Gubert, C., Panizzutti, B., Kapczinski, F., Rosa, A.R., Progesterone and its metabolites as therapeutic targets in psychiatric disorders. Expert Opin. Ther. Targets 18 (2014), 679–690.
11. Chan, A.F., Mortola, J.F., Wood, S.H., Yen, S.S., Persistence of premenstrual syndrome during low-dose administration of the progesterone antagonist RU 486. Obstet. Gynecol. 84 (1994), 1001–1005.
12. Cohen, L.S., Miner, C., Brown, E.W., Freeman, E., Halbreich, U., Sundell, K., McCray, S., Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries. Obstet. Gynecol. 100 (2002), 435–444.
13. Dennerstein, L., Lehert, P., Backstrom, T.C., Heinemann, K., The effect of premenstrual symptoms on activities of daily life. Fertil. Steril. 94 (2010), 1059–1064.
14. de Visser, S.J., van der Post, J.P., de Waal, P.P., Cornet, F., Cohen, A.F., van Gerven, J.M., Biomarkers for the effects of benzodiazepines in healthy volunteers. Br. J. Clin. Pharmacol. 55 (2003), 39–50.
15. Dougherty, D.M., Cherek, D.R., Bennett, R.H., The effects of alcohol on the aggressive responding of women. J. Stud. Alcohol 57 (1996), 178–186.
16. Endicott, J., Nee, J., Harrison, W., Daily record of severity of problems (DRSP): reliability and validity. Arch. Womens Ment. Health 9 (2006), 41–49.
17. Halbreich, U., Bergeron, R., Yonkers, K.A., Freeman, E., Stout, A.L., Cohen, L., Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstet. Gynecol. 100 (2002), 1219–1229.
18. Hammarback, S., Backstrom, T., A demographic study in subgroups of women seeking help for premenstrual syndrome. Acta Obstet. Gynecol. Scand. 68 (1989), 247–253.
19. Hedstrom, H., Bixo, M., Nyberg, S., Spigset, O., Zingmark, E., Backstrom, T., Studies of pharmacokinetic and pharmacodynamic properties of isoallopregnanolone in healthy women. Psychopharmacology (Berl) 203 (2009), 85–98.
20. Hommer, D.W., Matsuo, V., Wolkowitz, O., Chrousos, G., Greenblatt, D.J., Weingartner, H., Paul, S.M., Benzodiazepine sensitivity in normal human subjects. Arch. Gen. Psychiatry 43 (1986), 542–551.
21. Iacono, W.G., Lykken, D.T., Two-year retest stability of eye tracking performance and a comparison of electro-oculographic and infrared recording techniques: evidence of EEG in the electro-oculogram. Psychophysiology 18 (1981), 49–55.
22. Lopez, L.M., Kaptein, A.A., Helmerhorst, F.M., Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst. Rev., 2, 2012, CD006586.
23. Lovick, T.A., Griffiths, J.L., Dunn, S.M., Martin, I.L., Changes in GABA(A) receptor subunit expression in the midbrain during the oestrous cycle in Wistar rats. Neuroscience 131 (2005), 397–405.
24. Lundgren, P., Stromberg, J., Backstrom, T., Wang, M., Allopregnanolone-stimulated GABA-mediated chloride ion flux is inhibited by 3beta-hydroxy-5alpha-pregnan-20-one (isoallopregnanolone). Brain Res. 982 (2003), 45–53.
25. Maguire, J.L., Stell, B.M., Rafizadeh, M., Mody, I., Ovarian cycle-linked changes in GABA(A) receptors mediating tonic inhibition alter seizure susceptibility and anxiety. Nat. Neurosci. 8 (2005), 797–804.
26. Marjoribanks, J., Brown, J., O'Brien, P.M., Wyatt, K., Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst. Rev., 6, 2013, CD001396.
27. Martinez, P.E., Rubinow, D.R., Nieman, L.K., Koziol, D.E., Morrow, A.L., Schiller, C.E., Cintron, D., Thompson, K.D., Khine, K.K., Schmidt, P.J., 5alpha-reductase inhibition prevents the luteal phase increase in plasma allopregnanolone levels and mitigates symptoms in women with premenstrual dysphoric disorder. Neuropsychopharmacology 41 (2016), 1093–1102.
28. Nyberg, S., Backstrom, T., Zingmark, E., Purdy, R.H., Poromaa, I.S., Allopregnanolone decrease with symptom improvement during placebo and gonadotropin-releasing hormone agonist treatment in women with severe premenstrual syndrome. Gynecol. Endocrinol. 23 (2007), 257–266.
29. O'Brien, P.M., Backstrom, T., Brown, C., Dennerstein, L., Endicott, J., Epperson, C.N., Eriksson, E., Freeman, E., Halbreich, U., Ismail, K.M., Panay, N., Pearlstein, T., Rapkin, A., Reid, R., Schmidt, P., Steiner, M., Studd, J., Yonkers, K., Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD Montreal consensus. Arch. Womens Ment. Health 14 (2011), 13–21.
30. Rahman, M., Borra, V.B., Isaksson, M., Johansson, I.M., Ragagnin, G., Backstrom, T., Wang, M.D., A comparison of the pharmacological properties of recombinant human and rat alpha(1)beta(2)gamma(2L) GABA(A) receptors in Xenopus oocytes. Clin. Exp. Pharmacol. Physiol. 35 (2008), 1002–1011.
31. Sabaliauskas, N., Shen, H., Molla, J., Gong, Q.H., Kuver, A., Aoki, C., Smith, S.S., Neurosteroid effects at alpha4betadelta GABAA receptors alter spatial learning and synaptic plasticity in CA1 hippocampus across the estrous cycle of the mouse. Brain Res. 1621 (2015), 170–186.
32. Schmidt, P.J., Nieman, L.K., Danaceau, M.A., Adams, L.F., Rubinow, D.R., Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N. Engl. J. Med. 338 (1998), 209–216.
33. Segebladh, B., Borgstrom, A., Nyberg, S., Bixo, M., Sundstrom-Poromaa, I., Evaluation of different add-back estradiol and progesterone treatments to gonadotropin-releasing hormone agonist treatment in patients with premenstrual dysphoric disorder. Am. J. Obstet. Gynecol. 201:13 (2009), e131–138.
34. Shen, H., Gong, Q.H., Yuan, M., Smith, S.S., Short-term steroid treatment increases delta GABAA receptor subunit expression in rat CA1 hippocampus: pharmacological and behavioral effects. Neuropharmacology 49 (2005), 573–586.
35. Shen, H., Gong, Q.H., Aoki, C., Yuan, M., Ruderman, Y., Dattilo, M., Williams, K., Smith, S.S., Reversal of neurosteroid effects at alpha4beta2delta GABAA receptors triggers anxiety at puberty. Nat. Neurosci. 10 (2007), 469–477.
36. Shen, H., Mohammad, A., Ramroop, J., Smith, S.S., A stress steroid triggers anxiety via increased expression of alpha4betadelta GABAA receptors in methamphetamine dependence. Neuroscience 254 (2013), 452–475.
37. Stromberg, J., Haage, D., Taube, M., Backstrom, T., Lundgren, P., Neurosteroid modulation of allopregnanolone and GABA effect on the GABA-A receptor. Neuroscience 143 (2006), 73–81.
38. Sundstrom-Poromaa, I., Bixo, M., Bjorn, I., Nordh, O., Compliance to antidepressant drug therapy for treatment of premenstrual syndrome. J. Psychosom. Obstet. Gynaecol. 21 (2000), 205–211.
39. Sveindottir, H., Backstrom, T., Prevalence of menstrual cycle symptom cyclicity and premenstrual dysphoric disorder in a random sample of women using and not using oral contraceptives. Acta Obstet. Gynecol. Scand. 79 (2000), 405–413.
40. Timby, E., Balgard, M., Nyberg, S., Spigset, O., Andersson, A., Porankiewicz-Asplund, J., Purdy, R.H., Zhu, D., Backstrom, T., Poromaa, I.S., Pharmacokinetic and behavioral effects of allopregnanolone in healthy women. Psychopharmacology (Berl) 186 (2006), 414–424.
41. Timby, E., Backstrom, T., Nyberg, S., Stenlund, H., Wihlback, A.C., Bixo, M., Women with premenstrual dysphoric disorder have altered sensitivity to allopregnanolone over the menstrual cycle compared to controls-a pilot study. Psychopharmacology (Berl) 233 (2016), 2109–2117.
42. Toffoletto, S., Lanzenberger, R., Gingnell, M., Sundstrom-Poromaa, I., Comasco, E., Emotional and cognitive functional imaging of estrogen and progesterone effects in the female human brain: a systematic review. Psychoneuroendocrinology 50 (2014), 28–52.
43. van Broekhoven, F., Backstrom, T., van Luijtelaar, G., Buitelaar, J.K., Smits, P., Verkes, R.J., Effects of allopregnanolone on sedation in men, and in women on oral contraceptives. Psychoneuroendocrinology 32 (2007), 555–564.
44. van Wingen, G., van Broekhoven, F., Verkes, R.J., Petersson, K.M., Backstrom, T., Buitelaar, J., Fernandez, G., How progesterone impairs memory for biologically salient stimuli in healthy young women. J. Neurosci. 27 (2007), 11416–11423.
45. van Wingen, G.A., Ossewaarde, L., Backstrom, T., Hermans, E.J., Fernandez, G., Gonadal hormone regulation of the emotion circuitry in humans. Neuroscience 191 (2011), 38–45.
46. Wang, M., Hammarback, S., Lindhe, B.A., Backstrom, T., Treatment of premenstrual syndrome by spironolactone: a double-blind, placebo-controlled study. Acta Obstet. Gynecol. Scand. 74 (1995), 803–808.
47. Wang, M., Seippel, L., Purdy, R.H., Backstrom, T., Relationship between symptom severity and steroid variation in women with premenstrual syndrome: study on serum pregnenolone, pregnenolone sulfate, 5 alpha-pregnane-3,20-dione and 3 alpha-hydroxy-5 alpha-pregnan-20-one. J. Clin. Endocrinol. Metab. 81 (1996), 1076–1082.
48. Wang, M.D., Rahman, M., Zhu, D., Johansson, I.M., Backstrom, T., 3Beta-hydroxysteroids and pregnenolone sulfate inhibit recombinant rat GABA(A) receptor through different channel property. Eur. J. Pharmacol. 557 (2007), 124–131.
49. Wenzel, R.R., Bartel, T., Eggebrecht, H., Philipp, T., Erbel, R., Central-nervous side effects of midazolam during transesophageal echocardiography. J. Am. Soc. Echocardiogr. 15 (2002), 1297–1300.
50. Wittchen, H.U., Becker, E., Lieb, R., Krause, P., Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol. Med. 32 (2002), 119–132.
51. Wyatt, K.M., Dimmock, P.W., Ismail, K.M., Jones, P.W., O'Brien, P.M., The effectiveness of GnRHa with and without ‘add-back’ therapy in treating premenstrual syndrome: a meta analysis. BJOG 111 (2004), 585–593.
52. Yonkers, K.A., Brown, C., Pearlstein, T.B., Foegh, M., Sampson-Landers, C., Rapkin, A., Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet. Gynecol. 106 (2005), 492–501.